- Home
- PCSA vs UGRO Comparison
PCSA vs UGRO Comparison
Compare PCSA & UGRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCSA
- UGRO
- Stock Information
- Founded
- PCSA 2011
- UGRO 2014
- Country
- PCSA United States
- UGRO United States
- Employees
- PCSA N/A
- UGRO N/A
- Industry
- PCSA Biotechnology: Pharmaceutical Preparations
- UGRO Industrial Specialties
- Sector
- PCSA Health Care
- UGRO Consumer Discretionary
- Exchange
- PCSA Nasdaq
- UGRO Nasdaq
- Market Cap
- PCSA 3.3M
- UGRO 3.8M
- IPO Year
- PCSA N/A
- UGRO N/A
- Fundamental
- Price
- PCSA $0.21
- UGRO $0.60
- Analyst Decision
- PCSA Strong Buy
- UGRO Strong Buy
- Analyst Count
- PCSA 1
- UGRO 1
- Target Price
- PCSA $1.00
- UGRO $3.00
- AVG Volume (30 Days)
- PCSA 2.3M
- UGRO 14.7M
- Earning Date
- PCSA 10-29-2025
- UGRO 10-30-2025
- Dividend Yield
- PCSA N/A
- UGRO N/A
- EPS Growth
- PCSA N/A
- UGRO N/A
- EPS
- PCSA N/A
- UGRO N/A
- Revenue
- PCSA N/A
- UGRO $59,985,138.00
- Revenue This Year
- PCSA N/A
- UGRO N/A
- Revenue Next Year
- PCSA N/A
- UGRO $31.25
- P/E Ratio
- PCSA N/A
- UGRO N/A
- Revenue Growth
- PCSA N/A
- UGRO N/A
- 52 Week Low
- PCSA $0.15
- UGRO $0.26
- 52 Week High
- PCSA $1.50
- UGRO $1.92
- Technical
- Relative Strength Index (RSI)
- PCSA 52.56
- UGRO 62.04
- Support Level
- PCSA $0.18
- UGRO $0.57
- Resistance Level
- PCSA $0.20
- UGRO $0.64
- Average True Range (ATR)
- PCSA 0.02
- UGRO 0.09
- MACD
- PCSA 0.00
- UGRO 0.01
- Stochastic Oscillator
- PCSA 81.64
- UGRO 51.35
About PCSA Processa Pharmaceuticals Inc.
Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its regulatory science approach in the development of Next Generation Chemotherapy (NGC) oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small-molecule oncology drugs. The NGC products are new chemical entities, but the company works by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The three NGC treatments in its pipeline are PCS6422 (also referred to as NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem), and PCS11T, also referred to as NGC-Irinotecan (NGC-Iri).
About UGRO urban-gro Inc.
Urban-gro Inc is an integrated professional services and construction design-build firm. Its business focuses predominantly on providing fee-based knowledge-based services as well as the value-added reselling of equipment. The company offers value-added architectural, engineering, systems procurement and integration, and construction design-build solutions to customers operating in the controlled environment agriculture (CEA) and industrial and other commercial (Commercial) sectors. It derives revenue predominately from the sale of equipment systems, services, construction design-build, and other various immaterial contracts with customers.